MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL
Clinical trials for MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL explained in plain language.
Never miss a new study
Get alerted when new MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL trials appear
Sign up with your email to follow new studies for MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common asthma drug help with a rare muscle disease? new study launches.
Disease control Recruiting nowThis early-stage study is testing whether clenbuterol, a drug used for breathing problems, is safe for people with facioscapulohumeral muscular dystrophy (FSHD). About 30 adults with FSHD will receive one of three doses of the drug. Researchers will monitor side effects, heart ra…
Matched conditions: MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL
Phase: PHASE1 • Sponsor: Jeffrey Statland • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New study aims to sharpen tools for testing kids with rare muscle disease
Knowledge-focused Recruiting nowThis study is testing different ways to measure muscle strength and movement in children with a rare muscle disease called FSHD. The goal is to find the best tests to use in future studies of new treatments. About 80 children aged 5 to 17 with confirmed FSHD will take part. The r…
Matched conditions: MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
FSHD patients unite: new registry aims to accelerate research and care
Knowledge-focused Recruiting nowThis study creates a registry for people with facioscapulohumeral muscular dystrophy (FSHD) to share their health experiences and data. Up to 5,000 participants in the U.S. will provide information through surveys to help researchers better understand the disease and develop impr…
Matched conditions: MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL
Sponsor: FSHD Society • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC